source
- Inhibrx reports promising responses to OX40 immunotherapy in HPV-positive head and neck cancerInhibrx announced that its experimental immunotherapy targeting the protein OX40 produced measurable responses in patients with head and neck cancer, with the clearest activity observed in a small…
- BrainChild Bio raises $116 million to fund pivotal pediatric brain tumor CAR-T trialBrainChild Bio, a Seattle-based biotech, announced it has secured $116 million in financing to support a pivotal clinical trial of its CAR-T therapy aimed at pediatric brain tumors. The funding ro…